Kodiak Sciences reports Q3 EPS ($1.16), consensus ($1.04)

“Kodiak Sciences (KOD) has entered a period of strong, sustained momentum driven by compelling clinical data, accelerated execution and growing external enthusiasm…across all three of our late-stage programs,” said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. “Looking ahead, we expect this momentum to continue building as we enter an action-packed 2026 with all three of our Phase 3 assets on track for Phase 3 topline data readouts as well as our first planned BLA filing. On top of our late-stage programs, Kodiak’s early-stage pipeline is also advancing with increasing speed and conviction, positioning Kodiak for sustained scientific and pipeline leadership globally,” continued Dr. Perlroth.